HOME
CONTACT US
SITE MAP
ABOUT US
DRUG CANDIDATES
RESEARCH PROGRAMS
GPCR TECHNOLOGY
INVESTORS
CAREERS
Site Map
General
Home
Terms and Conditions
Privacy Statement
Contact Us
About Us
Corporate Overview
Officers
Directors
Corporate Partnerships
Drug Candidates
Pipeline
Lorcaserin (weight management)
APD811 (pulmonary arterial hypertension)
APD334 (autoimmune diseases, including multiple sclerosis)
CB2 (osteoarthritis and pain)
GPR119 receptor (type 2 diabetes)
APD597 (type 2 diabetes)
Temanogrel, formerly APD791 (arterial thrombosis)
APD125 (formerly for insomnia)
Research Programs
Overview
Cardiovascular
Central Nervous System
Inflammatory Diseases
Metabolic Diseases
GPCR Technology
Arena's GPCR Technologies
GPCR FAQ
Investors
Investor Overview
Press Releases
Events & Presentations
Analyst Coverage
Annual Reports
Corporate Governance
Executive Officers
Board of Directors
Governance Documents
Committee Composition
Stock Information
SEC Filings
Email Alerts
Contact Investor Relations
Careers
Overview
Benefits
Career Opportunities
Recruiters/Agencies
This page last updated: 05/19/2011
Additional Information regarding Arena is available in its SEC filings
© Copyright 2000-
2012
Arena Pharmaceuticals, Inc.
All Rights Reserverd
Terms and Conditions
Privacy Statement
ABOUT US
DRUG CANDIDATES
RESEARCH PROGRAMS
GPCR TECHNOLOGY
INVESTORS
CAREERS